MedTrace Logo

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

NCT04194242 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-12-28

No results posted yet for this study

Summary

This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of HEC96719, in healthy subjects.This study is the healthy adult subjects single ascending-dose research

Conditions

  • Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG

HEC96719 tablets

0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1

DRUG

Placebo tablet

0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-03
Primary Completion
2020-07-17
Completion
2020-07-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04194242 on ClinicalTrials.gov